Answers are grounded in this paper and cite their sources.
The hypereosinophilic syndrome may result from a novel fusion tyrosine kinase - FIP1L1-PDGFRalpha - that is a consequence of an interstitial chromosomal deletion. The acquisition of a T674I resistance mutation at the time of relapse demonstrates that FIP1L1-PDGFRalpha is the target of imatinib. Our data indicate that the deletion of genetic material may result in gain-of-function fusion proteins.
No takes yet. Share an insight, caveat, or question.
Cools et al. (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: